Henlius Biotech H1 2025 Financial ReportHenlius BiotechHenlius reports H1 2025 results: overseas profits soar 200%, global product expansion, and innovation pipeline growth, driving ‘Globalization 2.0’ and next-gen therapies worldwide.
Adaptimmune Sells Four Core Cell TherapiesAdaptimmuneAdaptimmune Therapeutics sells four core cell therapies to US WorldMeds for $85M, ensuring continued patient access and advancing development of TECELRA, Lete-Cel, Afami-Cel, and Uza-Cel.
CD19 Targeted Drugs: A "Lifeline" for Lymphoma Patients?BiotechExplore how CD19-targeted CAR-T and CAR-NK cell therapies are transforming treatment for relapsed/refractory B-cell lymphoma. Learn about their mechanisms, clinical outcomes, safety profiles, and future potential in cancer care.
Stem Cell Therapy: 5 Major ChallengesBiotechExplore the five major challenges in stem cell therapy, including sourcing, immune response, functional heterogeneity, post-transplant viability, and targeted delivery. Learn how these affect clinical outcomes.
BioNTech Acquires CureVac in $1.25B mRNA DealBioNTechBioNTech acquires CureVac in a $1.25 billion all-stock deal, expanding its mRNA cancer therapy pipeline and resolving ongoing litigation. The acquisition strengthens BioNTech’s oncology strategy and manufacturing capabilities.
Bristol Myers Squibb Bets on ACP3 in $1.35B DealBMSBristol Myers Squibb teams up with Philochem in a $1.35B radiopharma deal to develop OncoACP3, a novel prostate cancer therapy targeting ACP3, offering a potential alternative to PSMA-focused treatments.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
